These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9558187)

  • 21. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis.
    Fuchs D; Fruchter L; Fishel B; Holtzman M; Yaron M
    Clin Rheumatol; 1986 Dec; 5(4):527-30. PubMed ID: 3816102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Systemic sclerosis--clinical course and treatment possibilities].
    Szymańska E; Maj M; Rudnicka L
    Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide therapy for scleroderma.
    Akesson A
    Curr Opin Rheumatol; 1998 Nov; 10(6):579-83. PubMed ID: 9812219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis.
    Géher P; Gömör B
    Med Sci Monit; 2001; 7(1):105-7. PubMed ID: 11208503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
    Johns KR; Littlejohn GO
    J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S; Wigley FM; Wise R; Xiao H; Hummers L
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abatacept induces clinical improvement in patients with severe systemic sclerosis.
    de Paoli FV; Nielsen BD; Rasmussen F; Deleuran B; Søndergaard K
    Scand J Rheumatol; 2014; 43(4):342-5. PubMed ID: 25088011
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical characteristics of juvenile dermatomyositis].
    Constantin T; Ponyi A; Garami M; Gergely L; Fekete G; Dankó K
    Orv Hetil; 2003 Jun; 144(25):1245-50. PubMed ID: 12901181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The arthritis of inflammatory childhood myositis syndromes.
    Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
    J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Juvenile dermatomyositis].
    Tambić-Bukovac L; Malcić I; Prohić A
    Reumatizam; 2001; 48(1):27-33. PubMed ID: 12476739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclosporine as a treatment for multicentric reticulohistiocytosis.
    Chalom EC; Rosenstein ED; Kramer N
    J Rheumatol; 2000 Feb; 27(2):556. PubMed ID: 10685836
    [No Abstract]   [Full Text] [Related]  

  • 33. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
    Casale R; Generini S; Luppi F; Pignone A; Matucci-Cerinic M
    Arthritis Rheum; 2004 Aug; 51(4):665-9. PubMed ID: 15334442
    [No Abstract]   [Full Text] [Related]  

  • 34. [Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis].
    Nakashima S; Mori M; Miyamae T; Ito S; Ibe M; Aihara Y; Yokota S
    Ryumachi; 2002 Dec; 42(6):895-902. PubMed ID: 12632609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymoglobulin and cyclophosphamide as treatment for diffuse cutaneous systemic sclerosis.
    Holmberg LA; Furst DE; McSweeney PA; Nash RA
    J Rheumatol; 2009 Aug; 36(8):1839. PubMed ID: 19671826
    [No Abstract]   [Full Text] [Related]  

  • 36. Rituximab for rapidly progressive juvenile systemic sclerosis.
    Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
    Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scleroderma and failed response to alefacept.
    Chi GC; Hsu FS; Yang CC; Wei JC
    Rheumatology (Oxford); 2005 Oct; 44(10):1328-30. PubMed ID: 15972344
    [No Abstract]   [Full Text] [Related]  

  • 38. Two years of penicillamine for progressive systemic sclerosis: a case report.
    Thomson J; Milne JA
    Postgrad Med J; 1974 Aug; 50 Suppl 2():36-8. PubMed ID: 4467175
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclosporin A in progressive system sclerosis.
    Constantopoulos A
    Acta Paediatr; 1995 Jan; 84(1):69. PubMed ID: 7734904
    [No Abstract]   [Full Text] [Related]  

  • 40. Cyclosporin A in progressive system sclerosis.
    Constantopoulos A; Dracou C; Tsoumakas C
    Acta Paediatr; 1995 Jun; 84(6):604. PubMed ID: 7670238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.